Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy

被引：95

作者：

Lu, Jun ^{[1
,2
]}

Zhong, Hua ^{[1
]}

Chu, Tianqing ^{[1
]}

Zhang, Xueyan ^{[1
]}

Li, Rong ^{[1
]}

Sun, Jiayuan ^{[1
]}

Zhong, Runbo ^{[1
]}

Yang, Yuqin ^{[2
]}

Alam, Mohammad Shah ^{[3
]}

Lou, Yuqing ^{[1
]}

Xu, Jianlin ^{[1
]}

Zhang, Yanwei ^{[1
]}

Wu, Jun ^{[4
]}

Li, Xiaowei ^{[3
]}

Zhao, Xiaodong ^{[5
]}

Li, Kai ^{[6
]}

Lu, Liming ^{[2
,7
]}

Han, Baohui ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm Med, Shanghai 200030, Peoples R China

[2] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Cent Lab, Shanghai, Peoples R China

[3] Shanghai Jiao Tong Univ, Sch Biomed Engn, BioID Ctr, Shanghai, Peoples R China

[4] East China Normal Univ, Sch Life Sci, Shanghai, Peoples R China

[5] Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Shanghai, Peoples R China

[6] Tianjin Med Univ Canc Inst & Hosp, Dept Thorac Oncol, Natl Clin Res Ctr Canc, Tianjin, Peoples R China

[7] Shanghai Jiao Ton Univ, Shanghai Inst Immunol, Sch Med, Shanghai, Peoples R China

来源：

EUROPEAN RESPIRATORY JOURNAL | 2019年 / 53卷 / 03期

基金：

中国国家自然科学基金;

关键词：

MULTICENTER; SENSITIVITY; INHIBITION; STATISTICS; ACTIVATION; MUTATIONS; BLOCKADE;

D O I：

10.1183/13993003.01562-2018

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

100201 [内科学];

摘要：

Background: Anlotinib has been demonstrated in clinical trials to be effective in prolonging the progression-free survival (PFS) and overall survival (OS) of refractory advanced nonsmall cell lung cancer (NSCLC) patients. However, the underlying molecular mechanisms and predictive biomarkers of anlotinib are still unclear. Methods: A retrospective analysis of anlotinib administered to 294 NSCLC patients was performed to screen for underlying biomarkers of anlotinib-responsive patients. Transcriptome and functional assays were performed to understand the antitumour molecular mechanisms of anlotinib. Changes in serum CCL2 levels were analysed to examine the correlation of the anlotinib response between responders and nonresponders. Results: Anlotinib therapy was beneficial for prolonging OS in NSCLC patients harbouring positive driver gene mutations, especially patients harbouring the epithelial growth factor receptor (EGFR) T790M mutation. Moreover, anlotinib inhibited angiogenesis in an NCI-H1975-derived xenograft model via inhibiting CCL2. Finally, anlotinib-induced serum CCL2 level decreases were associated with the benefits of PFS and OS in refractory advanced NSCLC patients. Conclusions: Our study reports a novel anti-angiogenesis mechanism of anlotinib via inhibiting CCL2 in an NCI-H1975-derived xenograft model and suggests that changes in serum CCL2 levels may be used to monitor and predict clinical outcomes in anlotinib-administered refractory advanced NSCLC patients using third-line therapy or beyond.

引用

页数：12

共 36 条

[1]

Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma [J].

Ambrogio, Chiara ;

Gomez-Lopez, Gonzalo ;

Falcone, Mattia ;

Vidal, August ;

Nadal, Ernest ;

Crosetto, Nicola ;

Blasco, Rafael B. ;

Fernandez-Marcos, Pablo J. ;

Sanchez-Cespedes, Montserrat ;

Ren, Xiaomei ;

Wang, Zhen ;

Ding, Ke ;

Hidalgo, Manuel ;

Serrano, Manuel ;

Villanueva, Alberto ;

Santamaria, David ;

Barbacid, Mariano .

NATURE MEDICINE, 2016, 22 (03) :270-277

[2]

Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cells [J].

An, Jun ;

Xue, Ying ;

Long, Meijun ;

Zhang, Ge ;

Zhang, Junhang ;

Su, Hang .

ONCOTARGET, 2017, 8 (24) :39230-39240

[3]

[Anonymous], 2016, J CLIN ONCOL S

[4]

[Anonymous], ASCO PUBLICATION

[5]

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo [J].

Ashton, Susan ;

Song, Young Ho ;

Nolan, Jim ;

Cadogan, Elaine ;

Murray, Jim ;

Odedra, Rajesh ;

Foster, John ;

Hall, Peter A. ;

Low, Susan ;

Taylor, Paula ;

Ellston, Rebecca ;

Polanska, Urszula M. ;

Wilson, Joanne ;

Howes, Colin ;

Smith, Aaron ;

Goodwin, Richard J. A. ;

Swales, John G. ;

Strittmatter, Nicole ;

Takats, Zoltan ;

Nilsson, Anna ;

Andren, Per ;

Trueman, Dawn ;

Walker, Mike ;

Reimer, Corinne L. ;

Troiano, Greg ;

Parsons, Donald ;

De Witt, David ;

Ashford, Marianne ;

Hrkach, Jeff ;

Zale, Stephen ;

Jewsbury, Philip J. ;

Barry, Simon T. .

SCIENCE TRANSLATIONAL MEDICINE, 2016, 8 (325)

[6]

Circulating MCP-1 levels shows linkage to chemokine receptor gene cluster on chromosome 3: the NHLBI Family Heart Study follow-up examination [J].

Bielinski, S. J. ;

Pankow, J. S. ;

Miller, M. B. ;

Hopkins, P. N. ;

Eckfeldt, J. H. ;

Hixson, J. ;

Liu, Y. ;

Myers, R. H. ;

Arnett, D. K. .

GENES AND IMMUNITY, 2007, 8 (08) :684-690

[7]

Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis [J].

Bonapace, Laura ;

Coissieux, Marie-May ;

Wyckoff, Jeffrey ;

Mertz, Kirsten D. ;

Varga, Zsuzsanna ;

Junt, Tobias ;

Bentires-Alj, Mohamed .

NATURE, 2014, 515 (7525) :130-133

[8]

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[9]

Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study [J].

Chang, Gee-Chen ;

Tseng, Chien-Hua ;

Hsu, Kuo-Hsuan ;

Yu, Chong-Jen ;

Yang, Cheng-Ta ;

Chen, Kun-Chieh ;

Yang, Tsung-Ying ;

Tseng, Jeng-Sen ;

Liu, Chien-Ying ;

Liao, Wei-Yu ;

Hsia, Te-Chun ;

Tu, Chih-Yen ;

Lin, Meng-Chih ;

Tsai, Ying-Huang ;

Hsieh, Meng-Jer ;

Wu, Wen-Shuo ;

Chen, Yuh-Min .

LUNG CANCER, 2017, 104 :58-64

[10]

Microenvironmental regulation of tumour angiogenesis [J].

de Palma, Michele ;

Biziato, Daniela ;

Petrova, Tatiana V. .

NATURE REVIEWS CANCER, 2017, 17 (08) :457-474

← 1 2 3 4 →